NATHBIOGEN

Nath Bio-Genes (India) Share Price

₹190.22 -3.98 (-2.05%)

22 Dec, 2024 21:40

SIP TrendupStart SIP in NATHBIOGEN

Start SIP

Performance

  • Low
  • ₹190
  • High
  • ₹199
  • 52 Week Low
  • ₹167
  • 52 Week High
  • ₹264
  • Open Price₹199
  • Previous Close₹194
  • Volume20,389

Investment Returns

  • Over 1 Month + 10.37%
  • Over 3 Month -11.19%
  • Over 6 Month -8.96%
  • Over 1 Year -5.95%
SIP Lightning

Smart Investing Starts Here Start SIP with Nath Bio-Genes (India) for Steady Growth!

Invest Now

Nath Bio-Genes (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 8.8
  • PEG Ratio
  • -
  • Market Cap Cr
  • 362
  • P/B Ratio
  • 0.6
  • Average True Range
  • 8.41
  • EPS
  • 19.72
  • Dividend Yield
  • 1.1
  • MACD Signal
  • 1.56
  • RSI
  • 44.81
  • MFI
  • 50.6

Nath Bio-Genes (India) Financials

Nath Bio-Genes (India) Technicals

EMA & SMA

Current Price
₹190.22
-3.98 (-2.05%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹194.17
  • 50 Day
  • ₹196.07
  • 100 Day
  • ₹201.60
  • 200 Day
  • ₹204.38

Resistance and Support

193.07 Pivot Speed
  • R3 205.15
  • R2 202.07
  • R1 196.15
  • S1 187.15
  • S2 184.07
  • S3 178.15

What's your outlook on Nath Bio-Genes (India)?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nath Bio Genes India has an operating revenue of Rs. 350.84 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 12% is healthy, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 17 which is a POOR score indicating inconsistency in earnings, a RS Rating of 24 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 106 indicates it belongs to a poor industry group of Agricultural Operations and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nath Bio-Genes (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-23 Quarterly Results
2024-08-07 Quarterly Results
2024-05-08 Audited Results & Final Dividend
2024-01-18 Quarterly Results
2023-10-16 Quarterly Results
Date Purpose Remarks
2024-08-09 FINAL Rs.2.00 per share(20%)Final Dividend

Nath Bio-Genes (India) F&O

Nath Bio-Genes (India) Shareholding Pattern

45.6%
4.37%
0.18%
0%
31.53%
18.32%

About Nath Bio-Genes (India)

  • NSE Symbol
  • NATHBIOGEN
  • BSE Symbol
  • 537291
  • Managing Director
  • Mr. Satish Kagliwal
  • ISIN
  • INE448G01010

Similar Stocks to Nath Bio-Genes (India)

Nath Bio-Genes (India) FAQs

Nath Bio-Genes (India) share price is ₹190 As on 22 December, 2024 | 21:26

The Market Cap of Nath Bio-Genes (India) is ₹361.5 Cr As on 22 December, 2024 | 21:26

The P/E ratio of Nath Bio-Genes (India) is 8.8 As on 22 December, 2024 | 21:26

The PB ratio of Nath Bio-Genes (India) is 0.6 As on 22 December, 2024 | 21:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23